www.fdanews.com/articles/197912-kdx-diagnostics-earns-ce-mark-for-bladder-cancer-test
KDx Diagnostics Earns CE Mark for Bladder Cancer Test
July 6, 2020
California-based KDx Diagnostics has received a CE mark for URO17, its urine-based test for bladder cancer.
The noninvasive urine test can greatly reduce, if not eliminate, the need for an expensive in-bladder camera procedure, the company said.
Bladder cancer is among the most prevalent cancers worldwide and has a high recurrence rate that requires frequent retesting.